Back to News
The MHRA has issued a Class 4 Caution in Use Drug Alert regarding the modifications made to the syringe of the Epistatus Multidose Pack (Buccal Midazolam rescue medication manufactured by Special Products) - please click here to view the alert in full (use the attachment above). This alert is a "caution in use" to "ensure that all patients are informed that they should use the pipette graduations and not rely on the plunger stop".
The alert has been issued to hospitals, clinics, wholesalers, GPs and Community Pharmacists but further details can be obtained from the Special Products' Medical Enquiries team on 01932 690325.
Emergency medication Buccolam, which is used to treat prolongued convulsive seizures tht may progress to status epilepticus, has been given european approval for the treatment of babies over three months old and children under the age of 18.
The liquid form oral midazolam treatment, produced by pharmaceutical company Viropharma, comes in age-specific doses. The medication, which is administered in the buccal cavity (between the cheek and gums), has been shown in four clinical studies to be either comparable or superior to the current standard treatment, rectal diazepam.
There are other versions of buccal midazolam available.
Click here to order the brand new (January 2012) Guideline on Training Standards for the Administration of Buccal Midazolam
Back to News